Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Receives Average Rating of “Hold” from Analysts
Shares of Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) have been given an average rating of “Hold” by the nine ratings firms that are covering the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $22.42.
A number of equities analysts have recently commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $21.00 price target on shares of Lexicon Pharmaceuticals in a research report on Monday, September 12th. Wedbush reiterated an “outperform” rating and set a $28.00 price target (down previously from $30.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, May 24th. Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 11th. Citigroup Inc. lifted their price target on shares of Lexicon Pharmaceuticals from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, September 12th. Finally, Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Friday, September 9th.
Several institutional investors have recently bought and sold shares of LXRX. Paradigm Asset Management Co. LLC bought a new position in Lexicon Pharmaceuticals during the second quarter valued at about $115,000. First Mercantile Trust Co. raised its position in Lexicon Pharmaceuticals by 9.2% in the second quarter. First Mercantile Trust Co. now owns 10,700 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 900 shares during the last quarter. Alambic Investment Management L.P. acquired a new position in shares of Lexicon Pharmaceuticals during the second quarter valued at about $165,000. BlackRock Group LTD raised its position in shares of Lexicon Pharmaceuticals by 56.9% in the first quarter. BlackRock Group LTD now owns 14,217 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 5,158 shares in the last quarter. Finally, A.R.T. Advisors LLC acquired a new position in shares of Lexicon Pharmaceuticals during the first quarter valued at about $174,000.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/lexicon-pharmaceuticals-inc-nasdaqlxrx-receives-average-rating-of-hold-from-analysts.html
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) traded up 1.296% during trading on Tuesday, reaching $19.155. 268,178 shares of the company traded hands. Lexicon Pharmaceuticals has a 12 month low of $7.65 and a 12 month high of $19.46. The firm’s market capitalization is $1.99 billion. The firm has a 50-day moving average price of $15.99 and a 200-day moving average price of $14.14.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.04. Lexicon Pharmaceuticals had a negative net margin of 13.42% and a negative return on equity of 9.03%. The company had revenue of $20.10 million for the quarter, compared to analyst estimates of $12.36 million. During the same quarter last year, the firm posted ($0.27) earnings per share. The company’s quarterly revenue was up 5186.8% compared to the same quarter last year. Equities research analysts anticipate that Lexicon Pharmaceuticals will post ($1.54) EPS for the current year.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.